Yu-Li Su

17PUBLICATIONS
61CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 07, 2026
Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.

|Jun 19, 2026
Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer.

|Jun 01, 2026
Early Prostate-Specific Antigen Dynamics as Predictors of Treatment Response and Survival Outcomes in Patients with Castration-Resistant Prostate Cancer and Bone Metastases Undergoing Radium-223 Therapy.

|Apr 21, 2026
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

|Dec 17, 2024
Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors.

Liang-Yun Cheng, Po-Jung Su, Ming-Chun Kuo

|Feb 09, 2024
The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis.

Shih-Yu Huang, Po-Jung Su, Chang-Ting Lin

Pageof 3

Frequent Collaborators

5 joint publications

Hao-Lun Luo

3 joint publications

Jei-Ming Peng

3 joint publications

Yao-Chi Chuang

3 joint publications

Hui-Ying Liu